PHARMACOLOGY OF ETROLIZUMAB IN A PHASE 2 STUDY IN MODERATE TO SEVERELY ACTIVE ULCERATIVE COLITIS

(1) Genentech, Inc.

(2) Hospital Clinic-IDIBAPS

(3) Catholic University of Leuven

(4) Charité Medical School- Humboldt University of Berlin

(5) Newcastle University

(6) University of Kiel

(7) Tel Aviv Medical Center



This item was part of the IBD II session at UEG Week 2013

This item can be cited as: United European Gastroenterology Journal; 2013: 1 (Supplement 1) A375

You may be interested in:

ER STRESS AND AUTOPHAGY, ERMERGING PATHWAYS IN CROHN’S DISEASE
English, Aetiology / Causes, Inflammatory bowel disease, Abstract, 'IBD-ology', 2013

Categorisation:

  • Clinical Specialty
    • 'IBD-ology'
  • Diagnosis and Management
    • Medical management
  • Disease
    • Inflammatory bowel disease
  • Format
    • Abstract
  • Language
    • English
  • Year
    • 2013